salsalate + docosahexaenoic acid

salsalate + docosahexaenoic acid (DHA) is a combination of the nonsteroidal anti-inflammatory drug (NSAID) salsalate and the omega-3 fatty acid docosahexaenoic acid. This specific combination was utilized by Catabasis Pharmaceuticals as an active comparator arm in a Phase 1 crossover biomarker study (Study 103; NCT01670773) for the treatment of Duchenne muscular dystrophy (DMD). The study was designed to compare the NF-κB inhibitory effects of this unconjugated combination against edasalonexent (CAT-1004), which is a covalent conjugate of salicylic acid and DHA. Results from the trial demonstrated that while edasalonexent successfully inhibited NF-κB activity following a single dose, the equimolar combination of salsalate and DHA did not achieve significant inhibition, supporting the therapeutic rationale for the conjugated molecule over the simple combination of its components.

Other names

salsalate + DHAsalicylic acid + docosahexaenoic acid